 |
|
|
 |
| (as at 31 December 2009) |
| |
|
| Consolidated Balance Sheets |
2009 |
2008 |
| |
RM'000 |
RM'000 |
| |
|
|
| Total non-current assets |
|
843,219 |
| Total current assets |
|
1,279,835 |
| Total assets |
2,028,590 |
2,123,054 |
| |
|
|
| Financed by : |
|
|
| Share capital |
402,946 |
402,849 |
| Reserves |
33,134 |
30,046 |
| Retained profits |
284,389 |
314,621 |
| Total equity attributable to equity holders
of the company |
720,469 |
747,516 |
| Minority interests |
115,660 |
111,075 |
| Total equity |
836,129 |
858,591 |
| Total non-current liabilities |
476,331 |
220,588 |
| Total current liabilities |
716,130 |
1,043,875 |
| Total liabilities |
1,192,461 |
1,264,463 |
| Total equity and liabilities |
2,028,590 |
2,123,054 |
| |
|
|
| Consolidated Income Statements |
2009 |
2008 |
| |
RM'000 |
RM'000 |
| |
|
|
| Turnover |
1,571,809 |
2,165,459 |
| |
|
|
| Profit before taxation |
15,579 |
120,268 |
| Taxation |
(10,511) |
(34,767) |
| Profit after taxation |
5,068 |
85,501 |
| Minority interests |
10,888 |
(20,475) |
| Profit attributable to shareholders |
(5,820) |
65,026 |
| |
|
|
| Group Financial Ratios |
2009 |
2008 |
| |
|
|
| Profitability (%) |
|
|
| Turnover growth rate |
(27.40) |
54.98 |
| Profit before taxation as a % of turnover |
0.99 |
5.55 |
| Profit before taxation as a % of shareholders' funds |
2.16 |
16.09 |
| |
|
|
| Liquidity (%) |
|
|
| Current ratio |
1.50 |
1.23 |
| Acid test ratio |
0.97 |
0.73 |
| |
|
|
| Market Ratios (%) |
|
|
| Net assets per share |
1.79 |
1.86 |
| Earnings per share |
(1.44) |
16.1 |
| Net dividend per share |
8.0 |
12.1 |
| |
|
|
| Productivity |
|
|
| Turnover per employee (RM) |
813 |
1,145 |
| Total Assets per employee (RM) |
1,049 |
1,123 |
| Number of employees |
1,934 |
1,891 |
| |
|
|
| |
|
|
| # Based on Duopharma’s full-year results consolidation |
|
 |
 |
 |
|
| |
|
